Patients with HER2+ and ER+ disease underwent FDG-PET with trastuzumab and bevacizumab respectively at baseline and during treatment. no FDA approved Hsp90 inhibitor nor standardized assay to ascertain Hsp90 inhibition. This review summarizes the current status of both first and second generation Hsp90 inhibitors based on their chemical classification and Continue Reading